212 related articles for article (PubMed ID: 18055323)
1. Molecular biology of thyroid cancer initiation.
Riesco-Eizaguirre G; Santisteban P
Clin Transl Oncol; 2007 Nov; 9(11):686-93. PubMed ID: 18055323
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
3. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.
Acquaviva G; Visani M; Repaci A; Rhoden KJ; de Biase D; Pession A; Giovanni T
Histopathology; 2018 Jan; 72(1):6-31. PubMed ID: 29239040
[TBL] [Abstract][Full Text] [Related]
5. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
6. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract][Full Text] [Related]
7. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Kimura ET; Nikiforova MN; Zhu Z; Knauf JA; Nikiforov YE; Fagin JA
Cancer Res; 2003 Apr; 63(7):1454-7. PubMed ID: 12670889
[TBL] [Abstract][Full Text] [Related]
9. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
Sáez JM
Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
[TBL] [Abstract][Full Text] [Related]
10. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Hou P; Liu D; Shan Y; Hu S; Studeman K; Condouris S; Wang Y; Trink A; El-Naggar AK; Tallini G; Vasko V; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1161-70. PubMed ID: 17317825
[TBL] [Abstract][Full Text] [Related]
12. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
[TBL] [Abstract][Full Text] [Related]
13. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
Maciel RM; Kimura ET; Cerutti JM
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic alterations in papillary thyroid cancers of young patients.
Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
[TBL] [Abstract][Full Text] [Related]
15. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
16. Molecular Alterations in Thyroid Carcinoma.
Haroon Al Rasheed MR; Xu B
Surg Pathol Clin; 2019 Dec; 12(4):921-930. PubMed ID: 31672298
[TBL] [Abstract][Full Text] [Related]
17. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
Komminoth P
Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
[TBL] [Abstract][Full Text] [Related]
18. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
19. Follicular cell thyroid neoplasia: insights from genomics and The Cancer Genome Atlas research network.
Giordano TJ
Curr Opin Oncol; 2016 Jan; 28(1):1-4. PubMed ID: 26569424
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
